• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.24% Nasdaq Down0.22%

    Cepheid (CPHD)

    -NasdaqGS
    58.04 Down 3.09(5.05%) 3:11PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Cepheid
    904 Caribbean Drive
    Sunnyvale, CA 94089
    United States - Map
    Phone: 408-541-4191
    Fax: 408-541-4192
    Website: http://www.cepheid.com

    Details 
    Index Membership:N/A
    Sector:Technology
    Industry:Scientific & Technical Instruments
    Full Time Employees:1,400

    Business Summary 

    Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert Infinity System for high volume testing. The company sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; Life Technologies Corporation to develop reagents for use in the USPS BDS program; AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, and others to develop Xpert Carba-R, a rapid diagnostic test; and Paul G. Allen Family Foundation and the BMGF to develop Xpert Ebola, a rapid test that. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

    Key Statistics


    Company Websites 
    Home Page
    Investor Relations
    Search Yahoo! for:
    More on Cepheid

    Corporate Governance 
    Cepheid’s ISS Governance QuickScore as of Jun 1, 2015 is 2. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 2; Compensation: 4.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. John L. Bishop , 70
    Chairman, Chief Exec. Officer and Member of Equity Incentive Committee
    1.24M15.50M
    Mr. Thomas L. Gutshall , 77
    Co-Founder, Director, Member of Nominating & Governance Committee and Member of Compensation & Organizational Devel. Committee
    N/AN/A
    Mr. Warren C. Kocmond Jr., 55
    Chief Operating Officer and Exec. VP
    628.00K345.00K
    Mr. Michael Fitzgerald , 55
    Exec. VP of Global HR
    486.00K0.00
    Mr. Peter Farrell , 50
    Exec. VP of Worldwide Commercial Operations
    396.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders